Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh (RIGHT)
Primary Purpose
Gastrointestinal Diseases, Cardiovascular Diseases, Obesity
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Wholegrain rye
Wholegrain wheat
Refined wheat
Sponsored by
About this trial
This is an interventional basic science trial for Gastrointestinal Diseases
Eligibility Criteria
Inclusion Criteria:
• Age: 30 - 65 years
- Body mass index (BMI): 25 - 32 kg/m2
- Weight stable (<3 kg weight change during the last 6 months)
- Apparently healthy
- Informed consent signed
- Freezer capacity for 2 weeks bread provision
- Can attend all visits required for the study
Exclusion Criteria:
• Smoking on a daily basis
- Lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study
- Diagnosed with any form of diabetes or CVD
- Reported chronic GI disorders
- Antibiotic treatment 3 month before study start and during the study
- Use of pre- or probiotic 1 month before study start and during the study
- Lack of cooperation and adherence to the protocol
- Use of prescription medication will be evaluated on an individual basis
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Experimental
Experimental
Arm Label
Refined wheat
Wholegrain wheat
Wholegrain rye
Arm Description
Refined wheat grain, a variety of cereal foods providing no wholegrain
Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
Outcomes
Primary Outcome Measures
Gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
Subjective sensations of gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
Gut microbiota composition assessed using 16S in a single fecal sample
Gut microbiota compostion assessed using 16S in a single fecal sample
Secondary Outcome Measures
Anthropometric masures
Body weight and waist circumference, saggital abdominal diameter and body composition (fat mass and fat free mass assessed using DEXA)
Blood pressure
Diastolic and systolic blood pressure and heart rate assessed twice using an automated apparatus
Blood lipids, fasting concentrations of total, LDL and HDL cholesterol and triglyerides
Fasting concentrations of total, LDL and HDL cholesterol and triglyerides
Glucose metabolism, fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
Fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
Low-grade inflammation, fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
Fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
Appetite sensation
Fasting and postprandial (every 30 minutes for 240 minutes) sensation of hunger, satiety, fullness, prospective food intake, thirst and well being
Breath hydrogen assessed using a Hydrolyzer
Fasting and postprandial (every 30 minutes for 240 minutes) concentrations of H2 in exhaled breath assessed using a Hydrolyzer
Short chain fatty acids, fecal concentrations of short chain fatty acids
Fecal concentrations of short chain fatty acids
Fecal pH
Fecal pH assessed in homogenized fecal sample
Intestinal permeability, assessed by urinary excretion of lactulose and mannitol
Intestinal permeability is assessed by urinary excretion of lactulose and mannitol for 4 hours and 24 hours following an oral load of 10g lactulose and 2 g mannitol
Zonulin, fasting concentrations in plasma
Fasting concentrations of zonulin in plasma
Dietary intake, a weighted 4-day food record
a weighted 4-day food record will be used to assess energy intake and macronutrient (protein, fat, carbohydrates and dietaru fiber) composition
Compliance, measured by fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
Fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
Full Information
NCT ID
NCT02358122
First Posted
January 21, 2015
Last Updated
February 3, 2015
Sponsor
University of Copenhagen
Collaborators
Lantmännens Forskningsstiftelse
1. Study Identification
Unique Protocol Identification Number
NCT02358122
Brief Title
Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh
Acronym
RIGHT
Official Title
Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Unknown status
Study Start Date
September 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Copenhagen
Collaborators
Lantmännens Forskningsstiftelse
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A dietary intervention study designed as a randomized, controlled, parallel intervention of 6-weeks duration. A total of 75 participants will be included in the study and randomly allocated to one of three interventions (refined wheat, whoelgrain wheat or wholegrain rye). Clinincal examinations including anthropometric assessment, fecal, urine and fastign blood sampling, dietary assessment and a meal challenge will be done before (week 0) and after (week 6) the intervention. At timepoints week 0, 2, 4 and 6 questionnaires will be filled in concerning satisfaction with diet and gastrointestinal symptoms.
Detailed Description
A dietary intervention study designed as a randomized, controlled, parallel intervention of 6-weeks duration. A total of 75 participants will be included in the study and randomly allocated to one of three interventions (refined wheat, whoelgrain wheat or wholegrain rye). The randomization will be stratified according to sex and sex-specific median habitual cereal dietary fibre intake (16g/d for men and 13g/d for women). The randomization will be done by means of a randomization generator of the webpage (http://www.randomization.com). Recruitment and randomization will take place continuously during the study period, and therefore randomization will be done as mixed block randomization.
During the intervention study, participants are instructed to substitute all cereal products (e.g. bread, breakfast cereals, pasta) of their diet with the provided study products. The amount of provided study products will match the average intake of carbohydrate-rich products of the Danish population, which corresponds to ~200g of bread and cereal products per day. The participants will eat the study products in an ad libitum manner and b instructed to avoid other cereals in their diet including cake, biscuits, ready made meals and fast foods with the exception of White rice whis is allowed 1-2 times per week.
Clinincal examinations including anthropometric assessment, fecal, urine and fastign blood sampling, dietary assessment and a meal challenge will be done before (week 0) and after (week 6) the intervention. At timepoints week 0, 2, 4 and 6 questionnaires will be filled in concerning satisfaction with diet and gastrointestinal symptoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Diseases, Cardiovascular Diseases, Obesity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Refined wheat
Arm Type
Active Comparator
Arm Description
Refined wheat grain, a variety of cereal foods providing no wholegrain
Arm Title
Wholegrain wheat
Arm Type
Experimental
Arm Description
Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
Arm Title
Wholegrain rye
Arm Type
Experimental
Arm Description
Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
Intervention Type
Other
Intervention Name(s)
Wholegrain rye
Intervention Description
A variety of cereal foods providing >100g/day wholegrain from rye
Intervention Type
Other
Intervention Name(s)
Wholegrain wheat
Intervention Description
A variety of cereal foods providing >100g/day wholegrain from wheat
Intervention Type
Other
Intervention Name(s)
Refined wheat
Intervention Description
A variety of cereal foods providing 0g/day wholegrain
Primary Outcome Measure Information:
Title
Gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
Description
Subjective sensations of gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
Time Frame
Change from 0 to 6 weeks
Title
Gut microbiota composition assessed using 16S in a single fecal sample
Description
Gut microbiota compostion assessed using 16S in a single fecal sample
Time Frame
Change from 0 to 6 weeks
Secondary Outcome Measure Information:
Title
Anthropometric masures
Description
Body weight and waist circumference, saggital abdominal diameter and body composition (fat mass and fat free mass assessed using DEXA)
Time Frame
Change from 0 to 6 weeks
Title
Blood pressure
Description
Diastolic and systolic blood pressure and heart rate assessed twice using an automated apparatus
Time Frame
Change from 0 to 6 weeks
Title
Blood lipids, fasting concentrations of total, LDL and HDL cholesterol and triglyerides
Description
Fasting concentrations of total, LDL and HDL cholesterol and triglyerides
Time Frame
Change from 0 to 6 weeks
Title
Glucose metabolism, fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
Description
Fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
Time Frame
Change from 0 to 6 weeks
Title
Low-grade inflammation, fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
Description
Fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
Time Frame
Change from 0 to 6 weeks
Title
Appetite sensation
Description
Fasting and postprandial (every 30 minutes for 240 minutes) sensation of hunger, satiety, fullness, prospective food intake, thirst and well being
Time Frame
Change from 0 to 6 weeks
Title
Breath hydrogen assessed using a Hydrolyzer
Description
Fasting and postprandial (every 30 minutes for 240 minutes) concentrations of H2 in exhaled breath assessed using a Hydrolyzer
Time Frame
Change from 0 to 6 weeks
Title
Short chain fatty acids, fecal concentrations of short chain fatty acids
Description
Fecal concentrations of short chain fatty acids
Time Frame
Change from 0 to 6 weeks
Title
Fecal pH
Description
Fecal pH assessed in homogenized fecal sample
Time Frame
Change from 0 to 6 weeks
Title
Intestinal permeability, assessed by urinary excretion of lactulose and mannitol
Description
Intestinal permeability is assessed by urinary excretion of lactulose and mannitol for 4 hours and 24 hours following an oral load of 10g lactulose and 2 g mannitol
Time Frame
Change from 0 to 6 weeks
Title
Zonulin, fasting concentrations in plasma
Description
Fasting concentrations of zonulin in plasma
Time Frame
Change from 0 to 6 weeks
Title
Dietary intake, a weighted 4-day food record
Description
a weighted 4-day food record will be used to assess energy intake and macronutrient (protein, fat, carbohydrates and dietaru fiber) composition
Time Frame
Change from 0 to 6 weeks
Title
Compliance, measured by fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
Description
Fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
Time Frame
Change from 0 to 6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
• Age: 30 - 65 years
Body mass index (BMI): 25 - 32 kg/m2
Weight stable (<3 kg weight change during the last 6 months)
Apparently healthy
Informed consent signed
Freezer capacity for 2 weeks bread provision
Can attend all visits required for the study
Exclusion Criteria:
• Smoking on a daily basis
Lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study
Diagnosed with any form of diabetes or CVD
Reported chronic GI disorders
Antibiotic treatment 3 month before study start and during the study
Use of pre- or probiotic 1 month before study start and during the study
Lack of cooperation and adherence to the protocol
Use of prescription medication will be evaluated on an individual basis
12. IPD Sharing Statement
Citations:
PubMed Identifier
31504699
Citation
Christensen L, Vuholm S, Roager HM, Nielsen DS, Krych L, Kristensen M, Astrup A, Hjorth MF. Prevotella Abundance Predicts Weight Loss Success in Healthy, Overweight Adults Consuming a Whole-Grain Diet Ad Libitum: A Post Hoc Analysis of a 6-Wk Randomized Controlled Trial. J Nutr. 2019 Dec 1;149(12):2174-2181. doi: 10.1093/jn/nxz198.
Results Reference
derived
PubMed Identifier
28954842
Citation
Vuholm S, Nielsen DS, Iversen KN, Suhr J, Westermann P, Krych L, Andersen JR, Kristensen M. Whole-Grain Rye and Wheat Affect Some Markers of Gut Health without Altering the Fecal Microbiota in Healthy Overweight Adults: A 6-Week Randomized Trial. J Nutr. 2017 Nov;147(11):2067-2075. doi: 10.3945/jn.117.250647. Epub 2017 Sep 27.
Results Reference
derived
PubMed Identifier
28327566
Citation
Suhr J, Vuholm S, Iversen KN, Landberg R, Kristensen M. Wholegrain rye, but not wholegrain wheat, lowers body weight and fat mass compared with refined wheat: a 6-week randomized study. Eur J Clin Nutr. 2017 Aug;71(8):959-967. doi: 10.1038/ejcn.2017.12. Epub 2017 Mar 22.
Results Reference
derived
Learn more about this trial
Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh
We'll reach out to this number within 24 hrs